Rigel Pharmaceuticals Inc. (New)
RIGL •
Buy Open
Signal type
Buy
Status
Open
Open Price
$30.61
Stop Loss
$28.07
Performance
2.55%
Days Open
6
Signal Setup
Signal Type Buy
Status Open
Open Date Apr 9, 2026
Open Price $30.61
Stop Loss $28.07
Timespan Day
Company Profile
Name Rigel Pharmaceuticals Inc. (New)
Ticker RIGL
Market Cap $334.75M
Sector PHARMACEUTICAL PREPARATIONS
Latest Close $31.39
List Date Nov 29, 2000
Description
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Website Open Company Website